Han et al developed a prognostic score for evaluating a cancer patient being considered for a Phase I clinical trial. This can help to stratify a patient based on risk. The authors are from the Cancer Research UK Medical Oncology Unit at Churchill Hospital in Oxford, England.
Patient selection: A phase I trial patient: cancer patient usually has failed standard treatment or has a cancer for which there is no standard therapy. The trial helps to identify side effects, determine a maximum tolerated dose and evaluate tumor response.
Outcome: overall survival
Parameters:
(1) ECOG performance status
(2) white blood cell count in 10^9/L
(3) hemoglobin in g/dL
(4) serum LDH in IU/L
(5) number of sites with metastases
|
Parameter |
Finding |
Points |
|
ECOG PS |
0 or 1 |
0 |
|
|
2 to 4 |
1 |
|
WBC count |
<= upper limit normal |
0 |
|
|
> upper limit normal |
1 |
|
Hemoglobin |
>= 12 g/dL |
0 |
|
|
< 12 g/dL |
1 |
|
serum LDH |
<= upper limit normal |
0 |
|
|
> upper limit normal |
1 |
|
metastatic sites |
0 to 2 |
0 |
|
|
>= 3 |
1 |
score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the worse the overall survival.
|
Score |
Risk |
Median Survival |
|
0 or 1 |
good |
321 days |
|
2 |
intermediate |
257 days |
|
3 to 5 |
poor |
117 days |
Specialty: Hematology Oncology
